Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Continuous doxorubicin infusions. A pilot study in young patients].

U Bode1, M Erps, W Köhler

  • 1Universitäts-Kinderklinik Bonn.

Klinische Padiatrie
|May 1, 1988
PubMed
Summary

Continuous doxorubicin infusions show effectiveness in treating relapsed childhood cancers with low toxicity. This approach offers a good quality of life for pediatric oncology patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.

Journal of neuro-oncology·2019
Same author

Bloodstream infection in paediatric cancer centres--leukaemia and relapsed malignancies are independent risk factors.

European journal of pediatrics·2015
Same author

Stromal cells as trend-setters for cells migrating into the lymph node.

Mucosal immunology·2014
Same author

Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial.

Journal of neuro-oncology·2014
Same author

The intestinal micro-environment imprints stromal cells to promote efficient Treg induction in gut-draining lymph nodes.

Mucosal immunology·2013
Same author

Skin tolerance is supported by the spleen.

Scandinavian journal of immunology·2013

Area of Science:

  • Pediatric Oncology
  • Pharmacology
  • Cancer Treatment

Context:

  • Relapsed childhood malignancies present significant treatment challenges.
  • Conventional chemotherapy regimens can lead to substantial toxicity in young patients.
  • Evaluating novel drug delivery methods is crucial for improving outcomes.

Purpose:

  • To assess the efficacy and toxicity of continuous infusion doxorubicin in pediatric patients with relapsed malignancies.
  • To determine the optimal dosing and infusion schedule for this patient population.
  • To evaluate the impact on patient quality of life and the feasibility of ambulatory care.

Summary:

  • Eleven pediatric patients with relapsed malignancies received continuous infusions of doxorubicin (5-10 mg/m2/day) until mucositis onset.

Related Experiment Videos

  • Infusions were administered via central venous access, with toxicity primarily limited to mucositis, bone marrow depression, and neutropenia.
  • Tumor regression was observed in 8/11 patients, with no significant cardiac or liver toxicity noted.

    • Impact:

    • Continuous doxorubicin infusion demonstrates a favorable efficacy and toxicity profile for relapsed childhood cancers.
    • This administration method supports a good quality of life and facilitates ambulatory care, justifying further investigation.
    • Results support a phase II study of low-dose continuous infusion doxorubicin for relapsed pediatric tumors.